Prospects of antisense therapy technologies

Molecular Biology

Volumn 43, Issue 6, 2009, Pages 917-929

  Skoblov, M Yu ^a  

^a RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

Author keywords

Antisense oligonucleotides; Antisense therapy; Ribozymes; RNA interference

Indexed keywords

EID: 71449105039     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893309060028     Document Type: Review

References (91)

1. Miyagishi M., Hayashi M., Taira K. 2003. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13, 1-7.
2. Paterson B. M., Roberts B. E., Kuff E. L. 1977. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. USA. 74, 4370-4374.
3. Zamecnik P. C., Stephenson M. L. 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75, 280-284.
4. Izant J. G., Weintraub H. 1984. Inhibition of thymidine kinase gene expression by anti-sense RNA: A molecular approach to genetic analysis. Cell. 36, 1007-1015.
5. Mizuno T., Chou M. Y., Inouye M. 1984. A unique mechanism regulating gene expression: Translational inhibition by a complementary RNA transcript (micRNA). Proc. Natl. Acad. Sci. USA. 81, 1966-1970.
6. Simons R. W., Kleckner N. 1983. Translational control of IS10 transposition. Cell. 34, 683-691.
7. Crooke R. M., Graham M. J., Martin M. J., Lemonidis K. M., Wyrzykiewiecz T., Cummins LL. 2000. Metabolism of antisense oligonucleotides in rat liver homogenates. J. Pharmacol. Exp. Ther. 292, 140-149.
8. Eder P. S., DeVine R. J., Dagle I. M., Walder J. A. 1991. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res. Dev. 1, 141-151.
9. Manoharan M. 1999. 2′-Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration and conjugation. Biochim. Biophys. Acta. 1489, 117-130.
10. Crooke S. T. 2000. Progress in antisense technology: The end of the beginning. Methods Enzymol. 313, 3-45.
11. Inoue H., Hayase Y., Imura A., Iwau S., Miura K., Ohtsuka E. 1987. Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res. 15, 6131-6148.
12. Agrawal S., Zhao Q. 1998. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8, 135-139.
13. Shen L. X., Kandimalla E. R., Agrawal S. 1998. Impact of mixedbackbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. Bioorg. Med. Chem. 6, 1695-1705.
14. Goel S., Desai K., Bulgaru A., et al. 2003. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin. Cancer Res. 9, 4069-4076.
15. Kurreck J. 2003. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644.
16. Casey B. P., Glazer P. M. 2001. Gene targeting via triplehelix formation. Prog. Nucleic Acid Res. Mol. Biol. 67, 163-192.
17. Pestka S., Daugherty B. L., Jung V., Hotta K., Pestka R. K. 1984. AntimRNA: Specific inhibition of translation of single mRNA molecules. Proc. Natl. Acad. Sci. USA. 81, 7525-7528.
18. Mercatante D. R., Kole R. 2002. Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. Biochim. Biophys. Acta. 1587, 126-132.
19. Abe T., Suzuki S., Hatta T., Takai K., Yokota T., Takaku H. 1998. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells. Antiviral Chem. Chemother. 9, 253-262.
20. Roh H., Pippin J., Drebin J. A. 2000. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res. 60, 560-565.
21. Bielinska A., Kukowska Latallo J. F., Johnson J., Tomalia D. A., Baker J. R. 1996. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24, 2176-2182.
22. Haensler J., Szoka F. C. 1993. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconj. Chem. 4, 372-379.
23. Akhtar S., Hughes M. D., Khan A., Bibby M., Hussain M., Nawaz Q., Double J., Sayyed P. 2000. The delivery of antisense therapeutics. Adv. Drug Deliv. Rev. 44, 3-21.
24. Brigger I., Dubernet C., Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651.
25. Manoharan M. 2002. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 2, 103-128.
26. Sandrasagra A., Leonard S. A., Tang L., et al. 2002. Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 12, 177-181.
27. Brand R. M. 2001. Topical and transdermal delivery of antisense oligonucleotides. Curr. Opin. Mol. Ther. 3, 244-248.
28. Klibanov A. L., Maruyama K., Torchilin V. P., Huang L. 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235-237.
29. Zinker B. A., Rondinone C. M., Trevillyan J. M., Gum R. J., Clampit J. E., Waring J. F., et al. 2002. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA. 99, 11357-11362.
30. Field A. K. 1999. Oligonucleotides as inhibitors of human immunodeficiency virus. Curr. Opin. Mol. Ther. 1, 323-331.
31. Tsuboi R., Ueki R., Ogawa H. 2001. Third Intercontinental Meeting of Hair Research Societies, Tokyo, Japan. Abstract 075.
32. http://www. isispharm. com/product_pipeline. html.
33. Whitesell L., Rosolen A., Neckers L. M. 1991. In vivo modulation of N-myc expression by continous perfusion with an antisense oligonucleotide. Antisense Res. Dev. 1, 343-350.
34. Anfossi G., Gewirtz A. M., Calabretta B. 1989. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA. 86, 3379-3383.
35. Chen G., Oh S., Monia B. P., Stacey D. W. 1996. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271, 28259-28265.
36. Cioffi C. L., Garay M., Johnston J. F., et al. 1997. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of A-Raf and C-Raf in seruminduced proliferation. Mol. Pharmacol. 51, 383-389.
37. Cioffi C. L., Monia B. P. 2000. Evaluation of biological role of c-Jun N-terminal kinase using an antisense approach. Methods Enzymol. 314, 363-378.
38. Holt J. T., Redner R. L., Nienhuis A. W. 1988. An oligomer complementary to c-MYC mRNa inhibits proliferation of HL60 promyelocytic cells and induces differentiation. Mol. Cell Biol. 8, 963-973.
39. Jansen B., Schlagbauer-Wadl H., Brown B. D., et al. 1998. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4, 232-234.
40. Kondo Y., Koga S., Komata T., Kondo S. 2000. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene. 19, 2205-2211.
41. Leech S. H., Olie R. A., Simoes-Wust A. P., et al. 2000. Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment. Int. J. Cancer. 87, 582-590.
42. Li F., Ackermann E. J., Bennett C. F., et al. 1999. Pleiotropic cell division defects and apoptosis induced by interference with survivin function. Nature Cell Biol. 1, 461-466.
43. Mahon F. X., Ripoche J., Pigeonnier V., et al. 1995. Inhibition of chronic myelogenous leukaemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp. Hematol. 23, 1606-1611.
44. Tamm I., Wagner M. 2006. Antisense therapy in clinical oncology. Mol. Biotechnol. 33, 221-238.
45. Guo S., Kemphues K. J. 1995. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 81, 611-620.
46. Napoli C., Lemieux C., Jorgensen R. 1990. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 2, 279-289.
47. Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., Mello C. C. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391, 806-811.
48. Tuschl T., Zamore P. D., Lehmann R., et al. 1999. Targeted mRNA degradation by double-stranded RNA in vitro. Genes Devel. 24, 3191-3197.
49. Lee Y., Hur I., Park S. Y., Kim Y. K., Suh M. R., Kim V. N. 2006. The role of PACT in the RNA silencing pathway. EMBO J. 25, 522-532.
50. Tang G. 2005. siRNA and miRNA: An insight into RISCs. Trends Biochem Sci. 30, 106-114.
51. Bartel D. P. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116, 281-297.
52. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., Kim V. N. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature. 425, 415-419.
53. Yi R., Qin Y., Macara I. G., Cullen B. R. 2003. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17, 3011-3016.
54. Chendrimada T. P., Gregory R. I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., Shiekhattar R. 2005. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 436, 740-744.
55. Kiriakidou M., Nelson P. T., Kouranov A., Fitziev P., Bouyioukos C., Mourelatos Z., Hatzigeorgiou A. 2004. A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 18, 1165-1178.
56. Lewis B. P., Burge C. B., Bartel D. P. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120, 15-20.
57. Ryazansky S. S., Gvozdev V. A. 2008. Small RNAs and carcinogenesis. Biokhimiya. 73, 640-655.
58. http://www. regulusrx. com/therapeutic-focus/therapeutic-areas. php.
59. http://www. santaris. com/frame. cfm?sprog=2& grp=4& menu=1.
60. Meister G., Landthaler M., Patkaniowska A., Dorsett Y., Teng G., Tuschl T. 2004. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell. 15, 185-197.
61. Pillai R. S., Bhattacharyya S. N., Artus C. G., Zoller T., Cougot N., Basyuk E., Bertrand E., Filipowicz W. 2005. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 309, 1573-1576.
62. Kiriakidou M., Tan G. S., Lamprinaki S., de Planell-Saguer M., Nelson P. T., Mourelatos Z. 2007. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell. 129, 1141-1151.
63. Wassenegger M. 2005. The role of the RNAi machinery in heterochromatin formation. Cell. 122, 13-16.
64. Weinberg M. S., Villeneuve L. M., Ehsani A., Amarzguioui M., Aagaard L., Chen Z. X., Riggs A. D., Rossi J. J., Morris K. V. 2006. The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA. 12, 256-262.
65. Ting A. H., Schuebel K. E., Herman J. G., Baylin S. B. 2005. Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nature Genet. 37, 906-910.
66. Galvani A., Sperling L. 2002. RNA interference by feeding in Paramecium. Trends Genet. 18, 11-12.
67. Shuey D. J., McCallus D. E., Giordano T. 2002. RNAi: Gene silencing in therapeutic intervention. Drug Discov. Today. 7, 1040-1046.
68. Caplen N. J., Fleenor J., Fire A., Morgan R. A. 2000. dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene. 252, 95-105.
69. Brummelkamp T. R., Bernards R., Agami R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296, 550-553.
70. Zeng Y., Wagner E. J., Cullen B. R. 2002. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell. 9, 1327-1333.
71. http://www. secinfo. com/d12TC3. z5K9. b. htm.
72. http://phx.corporate-ir.net/phoenix.zhtml?c=141787&p=irol-newsArticle&ID=761407&highlight.
73. http://www. stockhideout. com/big-board-stocks-options/8440-merck-buy-biotech-firm-fro-1-1b. html.
74. http://www.medicalnewstoday.com/articles/44387.php.
75. http://www.medicalnewstoday.com/articles/49334.php.
76. http://www.benitec.com/therapeutic.php.
77. http://www.rnainews.com/issues/6_4/features/144620-1.html.
78. http://www. drugresearcher. com/Tools-and-techniques/Sirna-launches-RNAi-asthma-program.
79. http://www.redorbit.com/news/health/225691/cytrx_announces_the_advancement_of_rip140_sirna_into_development_for/index. html.
80. http://www. dddmag. com/News-Roche-Acquires-Mirus-Bio. aspx.
81. http://www. mirusbio. com/therapeuticpipeline.
82. Cech T. R. 1987. The chemistry of self-splicing RNA and RNA enzymes. Science. 236, 1532-1539.
83. http://wsyachina. narod. ru/chemistry/molecular_evolution_2. html.
84. Symons R. H. 1992. Small catalytic RNAs. Annu. Rev. Biochem. 61, 641-671.
85. Fedor M. J. 2000. Structure and function of the hairpin ribozyme. J. Mol. Biol. 297, 269-291.
86. Dahm S. C., Uhlenbeck O. C. 1991. Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry. 30, 9464-9469.
87. Breaker R. R., Joyce G. F. 1994. A DNA enzyme that cleaves RNA. Chem. Biol. 1, 223-229.
88. Baum D. A., Silverman S. K. 2008. Deoxyribozymes: Useful DNA catalysts in vitro and in vivo. Cell. Mol. Life Sci. 65, 2156-2174.
89. Vorobieva M. A., Kovalev N. A., Zenkova M. A., Veniaminova A. G., Vlasov V. V. 2006. Hammerhead binary ribozymes. Vestn. VOGiS. 10, 321-330.
90. Macejak D. G., Jensen K. L., Jamison S. F., Domenico K., Roberts E. C., Chaudhary N., von Carlowitz I., Bellon L., Tong M. J., Conrad A., Pavco P. A., Blatt L. M. 2000. Inhibition of hepatitis C virus (HCV) RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology. 31, 769-776.
91. Sandberg J. A., Parker V. P., Blanchard K. S., Sweedler D., Powell J. A., Kachensky A., Bellon L., Usman N., Rossing T., Borden E., Blatt L. M. 2000. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40, 1462-1469.